AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics ...

AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a ...

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a ...

AbbVie said its recently acquired emraclidine drug candidate for schizophrenia missed the key goal in a pair of mid-stage studies, sending the biopharmaceutical company's shares down more than 10% in ...

AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, sending its ...

Investing.com - AbbVie (NYSE: ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia ...

(Bloomberg) -- AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...